Abstract

To the Editor, I read with great interest the article by Sun et al. [1]. Pentoxifylline may exert a number of renoprotective effects, besides its role in attenuating diabetic nephropathy. Pentoxifylline attenuates kidney damage secondary to hepatic ischemia/reperfusion injury. It mediates this action by decreasing malondialdehyde levels [2]. Simultaneously, it restores intracellular glutathione. As a result, oxidative injury to the kidneys is mitigated. Obviously, conditions such as hepato-renal syndrome can be avoided with pentoxifylline pretreatment. The coming years may very well see increased use of pentoxifylline as a prophylactic agent to prevent hepatorenal syndrome in patients with concurrent cirrhosis and ascites. Pentoxifylline is also beneficial in chronic renal disease. It benefits the kidneys by stabilizing renal function and the glomerular filtration rate. Concurrent decreases in inflammatory markers such as tissue necrosis factor-α and high-sensitivity C-reactive protein reflect the attenuation of inflammatory damage in the kidneys. The interleukin-6 level also decreases at the same time [3]. In addition, pentoxifylline helps reduce proteinuria in chronic kidney disease (CKD) patients. Renke et al. [3] recently reported a 26% decline in proteinuria following pentoxifylline therapy in comparison with placebo therapy. Pentoxifylline also decreases proteinuria in CKD patients following renal transplantation. Moreover, pentoxifylline modulates hepcidin function and augments iron release, thereby improving hemoglobin levels in CKD patients. By virtue of its antioxidant properties, pentoxifylline also mitigates and reduces renal damage secondary to exposure to cigarette smoke. Similarly, pentoxifylline is of benefit in cardiac surgery because it prevents and attenuates acute renal injury [4]. When used in conjunction with albumin, pentoxifylline protects the kidneys from injury following endotoxemic shock, by decreasing inducible nitric oxide synthase expression in the kidneys [5]. Similarly, the postlaparoscopy administration of pentoxifylline attenuates renal ischemia associated with laparoscopy. These examples clearly illustrate the renoprotective effects of pentoxifylline.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.